Amid the rapid advancement of modern medicine, cardiovascular diseases, kidney diseases, and metabolic disorders have emerged as major global health challenges. These conditions do not exist in isolation; instead, they are interrelated and interactive, forming a complex disease spectrum known as the Cardio-Kidney-Metabolic Syndrome (CKM). Traditional single-disease management models are no longer sufficient to meet clinical needs, making multidisciplinary integrated management an inevitable trend. Professor Pan Qi from Beijing Hospital focuses on the integrated management of CKM syndrome, exploring in depth how innovative management strategies and technological tools can break down barriers between traditional specialties, providing new insights and methods for clinical practice.
The integrated management concept of CKM mainly encompasses three core dimensions:First, breaking down specialty silos by regarding obesity, diabetes, cardiovascular diseases, and chronic kidney diseases as an interconnected disease spectrum, emphasizing holistic treatment rather than fragmented interventions.Second, precise staging-based intervention: CKM is classified into Stages 0 to 4, with clear individualized therapeutic goals set for each stage to avoid one-size-fits-all approaches and enhance treatment precision.Third, strengthening risk assessment and early warning mechanisms to prevent missed diagnoses or delayed interventions caused by over-reliance on single indicators in traditional models.
Compared with conventional single-disease management, integrated CKM management reshapes chronic disease care through four key transformations:
Shifting the prevention and treatment frontier forward: Initiate risk factor screening starting in childhood. Leveraging a community-hospital collaborative early intervention system, the core focus transitions from treating established diseases to preventing preclinical conditions. For Stage 0-1 patients, lifestyle modification and standardized monitoring are prioritized to reverse or slow disease progression.
Optimizing resource allocation and grassroots clinical capacity building: Standardized clinical pathways reduce diagnostic decision-making barriers for primary care physicians. Routine clinical data are utilized for rapid cardiovascular risk stratification and treatment guidance, while remote monitoring technologies alleviate the workload burden on tertiary hospitals.
Accelerating drug research and clinical translation: Promote the widespread application of multi-organ protective medications, including Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2is), and Nonsteroidal Mineralocorticoid Receptor Antagonists (MRAs).
Building a physician-patient collaborative health ecosystem: Integrate systematic patient education into routine management. Personalized intervention plans are delivered via mobile applications to empower patients and improve long-term self-management adherence.